Angiotensin I (Human, Synthetic)

<strong>Angiotensin I (Human)</strong>_x000D_ <strong>Catalog number:</strong> B2010574_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 1 mg_x000D_ <strong>Molecular Weight or Concentration:</strong> 1296 Da_x000D_ <strong>Supplied as:</strong> Powder_x000D_ <strong>Applications:</strong> molecular tool in the study of the renin-angiotensin system_x000D_ <strong>Storage:</strong> -20C_x000D_ <strong>Keywords:</strong> Hypertensin I_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Bellomo R, Wunderink RG, Szerlip H, English SW, Busse LW, Deane AM, Khanna_x000D_ AK, McCurdy MT, Ostermann M, Young PJ, Handisides DR, Chawla LS, Tidmarsh GF,_x000D_ Albertson TE. Angiotensin_I and angiotensin_II concentrations and their ratio in_x000D_ catecholamine-resistant vasodilatory shock. Crit Care. 2020 Feb 6;24(1):43._x000D_ _x000D_ 2: Sim MK. Des-aspartate-angiotensin_I, a novel angiotensin AT(1) receptor drug._x000D_ Eur J Pharmacol. 2015 Aug 5;760:36-41._x000D_ _x000D_ 3: Miziołek B, Bergler-Czop B, Kucharz E, Kotyla P, Kopeć-Mędrek M, Widuchowska_x000D_ M, Sieńczyk M, Brzezińska-Wcisło L. Significance of the angiotensin_I / angiotensin_II /angiotensin_(1-7) axis in the pathogenesis of systemic_x000D_ sclerosis. J Eur Acad Dermatol Venereol. 2020 Mar;34(3):558-564._x000D_ _x000D_ 4: Ferrario CM. Angiotensin_I, angiotensin _II and their biologically active_x000D_ peptides. J Hypertens. 2002 May;20(5):805-7._x000D_ _x000D_ 5: Arita M, Matsuyama Y. [Angiotensin_I]. Nihon Rinsho. 1995 Mar;53 Su Pt_x000D_ 2:695-8. Japanese._x000D_ _x000D_ 6: Lee KO, Tian EF, Cai MH, Wang H, Chan YH, Sim MK. Bioavailability of Orally_x000D_ Administered Des-Aspartate-Angiotensin I in Human Subjects. Drugs R D. 2018_x000D_ Mar;18(1):51-54._x000D_ _x000D_ 7: Santos RA. Angiotensin_(1-7). Hypertension. 2014 Jun;63(6):1138-47._x000D_ _x000D_ 8: Simões E Silva AC, Teixeira MM. ACE inhibition, ACE2 and angiotensin_(1-7)_x000D_ axis in kidney and cardiac inflammation and fibrosis. Pharmacol Res. 2016_x000D_ May;107:154-162._x000D_ _x000D_ 9: Kuipers A, Moll GN, Wagner E, Franklin R. Efficacy of lanthionine-stabilized_x000D_ angiotensin-(1-7) in type_I and type_II diabetes mouse models. Peptides. 2019_x000D_ Feb;112:78-84._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/20026757/">10: Ferrario CM. New physiological concepts of the renin-angiotensin system from_x000D_ the investigation of precursors and products of angiotensin I metabolism._x000D_ Hypertension. 2010 Feb;55(2):445-52. </a>_x000D_ _x000D_ <strong>Products Related to Angiotensin_I (Human)</strong><a href="https://moleculardepot.com/product-category/Peptides/">: Peptides</a>